Slingshot members are tracking this event:

Preclinical Data Released on Moleculin's (MBRX) Annamycin in Lung Metastases

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Management Comment "We are very encouraged by this data, as we believe it further demonstrates Annamycin's anti-cancer activity against tumors that evade therapies that may be initially effective in their primary location of origin, but are protected by metastasis to sanctuary organs. In the case of sarcomas treated with the current standard of care, doxorubicin, tumors may be initially responsive in their primary location, but become unresponsive after metastasis to the lungs, which eventually becomes the most likely cause of patients' death," commented Walter Klemp, Chairman and CEO of Moleculin. "This research also sheds light on why doxorubicin, the current standard of care for many types of cancer, is not effective against lung-localized cancer. Subsequently, we believe that Annamycin's ability in animal models to effectively accumulate in the lungs without noticeable side effects offers unique therapeutic opportunities that should be explored for the benefit of cancer patients with lung-localized tumors."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 25, 2020
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Annamycin, Lung Metastases, Resistant Tumor